Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Target Lowered at JPMorgan Chase & Co.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) had its price objective cut by JPMorgan Chase & Co. from $19.00 to $17.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 121.35% from the stock’s current price.

Several other equities research analysts have also weighed in on ENTA. Wall Street Zen lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, October 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

Get Our Latest Stock Report on Enanta Pharmaceuticals

Enanta Pharmaceuticals Price Performance

Shares of ENTA traded down $0.30 during midday trading on Friday, reaching $7.68. The stock had a trading volume of 152,232 shares, compared to its average volume of 221,242. The company has a market cap of $223.64 million, a price-to-earnings ratio of -3.27 and a beta of 0.75. The company’s fifty day simple moving average is $11.59 and its two-hundred day simple moving average is $13.00. Enanta Pharmaceuticals has a 1-year low of $7.63 and a 1-year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last posted its earnings results on Monday, November 16th. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 64.32%. The business had revenue of $12.87 million during the quarter, compared to analysts’ expectations of $14.62 million. On average, sell-side analysts forecast that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC increased its stake in Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after buying an additional 54,396 shares during the period. Jupiter Topco LLC purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $53,252,000. BlackRock Inc. acquired a new position in shares of Enanta Pharmaceuticals during the second quarter worth about $47,304,000. ADAR1 Capital Management LLC purchased a new position in Enanta Pharmaceuticals during the second quarter worth about $19,603,000. Finally, Spruce Street Capital LP acquired a new stake in Enanta Pharmaceuticals in the second quarter valued at about $15,873,698. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Read More

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.